<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844310</url>
  </required_header>
  <id_info>
    <org_study_id>CACT1215-01</org_study_id>
    <nct_id>NCT01844310</nct_id>
  </id_info>
  <brief_title>Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection</brief_title>
  <official_title>Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of RAL-based regimen in&#xD;
      treatment-experienced patients with resistant HIV infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In our study, both efficacy and safety of raltegravir(RAL)-based therapy will be assessed.&#xD;
      300 treatment-experienced patients with drug-resistant HIV will be randomized to two arms&#xD;
      (2:1). Group A (n=200) will be assigned with RAL-based regimen (RAL+TDF+LPV/r).Group B&#xD;
      (n=100) will be assigned with current second-line regimen in China (3TC+TDF+LPV/r). Both&#xD;
      virological and immunological profiles and responses at baseline and at week 4, 8, 12, 24,&#xD;
      36, and 48 will be evaluated. This study will be the first large-scale, multicenter,&#xD;
      randomized, prospective RAL-based therapy study in China for HIV/AIDs patients. The result&#xD;
      will provide proves for further practical antiviral therapy for China or other&#xD;
      resource-limiting countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 400 copies/mL at week 48</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 40 copies/mL at week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4 count at week 48</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities in the two treatment arms from baseline to week 48</measure>
    <time_frame>through week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>AIDS/HIV PROBLEM</condition>
  <arm_group>
    <arm_group_label>RAL +TDF+ LPV/r</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3TC+ TDF+LPV/r</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAL+TDF+LPV/r</intervention_name>
    <description>Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).</description>
    <arm_group_label>RAL +TDF+ LPV/r</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3TC+TDF+LPV/r</intervention_name>
    <description>Group B will be assigned with 3TC+TDF+LPV/r</description>
    <arm_group_label>3TC+ TDF+LPV/r</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-65 years&#xD;
&#xD;
          2. HIV seropositive and confirmed by western blot&#xD;
&#xD;
          3. have taken first line antiretroviral therapy for over one year and have any one of the&#xD;
             criteria listed below (viral load of all the patients meeting these criteria should be&#xD;
             confirmed at PUMCH laboratory)&#xD;
&#xD;
               1. Viral load more than 400 copies/ml&#xD;
&#xD;
               2. Viral rebound (confirmed by HIV RNA more than 400 copies/ml after virologic&#xD;
                  suppression)&#xD;
&#xD;
               3. When viral load cannot be monitored, patients experience immunologic failure who&#xD;
                  meet at least one of the criteria listed below will be enrolled:&#xD;
&#xD;
                    -  CD4 count equal to or lower than baseline level with first-line therapy,on&#xD;
                       two occasions over three months apart&#xD;
&#xD;
                    -  CD4 count with 50 percentage fall from the on-treatment peak value&#xD;
&#xD;
                    -  persistent CD4 count levels less than 100 cells/μl after over one-year&#xD;
                       antiretroviral therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous use of protease inhibitors&#xD;
&#xD;
          -  Previous use of integrase inhibitors&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  poor compliance and drug interaction,&#xD;
&#xD;
          -  opportunistic infections or malignancy at recruitment; or opportunistic infections&#xD;
             within three months but still unstable within 14 days prior to recruitment&#xD;
&#xD;
          -  HBsAg positive&#xD;
&#xD;
          -  patients with the any of the following test results during screening for inclusion:&#xD;
             WBC count&lt;2000/μl, neutrophil count&lt;1000/μl, Hb&lt;9g/dl, platelet count&lt;75000/μl, serum&#xD;
             creatinine&gt;1.5 ULN, transaminases or alkaline phosphatase &gt;3 ULN, total bilirubin&gt;2&#xD;
             ULN, serum creatinine kinase&gt;2 ULN&#xD;
&#xD;
          -  CCr&lt;60 ml/min&#xD;
&#xD;
          -  Current intravenous drug use&#xD;
&#xD;
          -  Severe neuropathy or mental disorder&#xD;
&#xD;
          -  history of alcohol abuse and unable to withdrawal&#xD;
&#xD;
          -  Severe peptic ulcer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Taisheng Li, MD</last_name>
    <phone>86-10-69155086</phone>
    <email>litsh@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Lv, MD</last_name>
      <phone>86-10-69155082</phone>
      <email>lvweipumch@163.com</email>
    </contact>
    <investigator>
      <last_name>Taisheng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>April 26, 2013</last_update_submitted>
  <last_update_submitted_qc>April 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>LI Taisheng</investigator_full_name>
    <investigator_title>director of the Department of Infectious Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

